"Designing Growth Strategies is in our DNA"

mRNA Influenza Vaccines Market Size, Share & Industry Analysis, By Product Type (Standalone and Combination Vaccines), By Indication (Seasonal Influenza, Pre-pandemic/Pandemic Influenza, and Broad-Spectrum/Universal Influenza), By Technology (Conventional Non-Replicating mRNA, Self-Amplifying mRNA, and Trans-Amplifying RNA), By Valency (Monovalent, Trivalent, and Quadrivalent), By Age Group (Pediatric, 18-49, 50-64, and 65+ Years), By Distribution Channel (Government Health Programs, Hospitals & Vaccination Clinics, and Retail Pharmacies & Drug Stores), and Regional Forecast, 2026-2034

Last Updated: September 17, 2026 | Format: PDF | Report ID: FBI119161

 

Buy Now

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
    5. Market Challenges
  4. Key Insights
    1. Clinical Pipeline and Development Stage Analysis, By Key Players 
    2. Seasonal Influenza Vaccination Coverage and Target Population Analysis, By Key Regions/Countries 
    3. Pricing, Reimbursement, Government Procurement, and Tender Landscape 
    4. Regulatory Scenario, By Key Players, By Key Regions
    5. New Product Launches, By Key Players
    6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    7. PESTEL Analysis
    8. Porter’s Five Force Model
  5. Global mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines
      2. Combination mRNA Influenza Vaccines
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Germany
      2. U.K. 
      3. France 
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type              
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication    
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency         
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group   
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel              
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of the Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Moderna, Inc.
      2. GSK plc
      3. Pfizer Inc.
      4. Arcturus Therapeutics Holdings Inc.
      5. BioNTech SE
      6. SANOFI
      7. AstraZeneca PLC
      8. CanSino Biologics Inc.
      9. Ethris GmbH
      10. CSL
      11. Tiba Biotech LLC
      12. AIM Vaccine Co., Ltd.
      13. Immorna (Hangzhou) Biotechnology Co., Ltd.
      14. RNACure BioPharma (Shanghai) Co., Ltd. 
      15. Merck & Co., Inc.
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
    5. Market Challenges
  4. Key Insights
    1. Clinical Pipeline and Development Stage Analysis, By Key Players 
    2. Seasonal Influenza Vaccination Coverage and Target Population Analysis, By Key Regions/Countries 
    3. Pricing, Reimbursement, Government Procurement, and Tender Landscape 
    4. Regulatory Scenario, By Key Players, By Key Regions
    5. New Product Launches, By Key Players
    6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    7. PESTEL Analysis
    8. Porter’s Five Force Model
  5. Global mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines
      2. Combination mRNA Influenza Vaccines
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Germany
      2. U.K. 
      3. France 
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type          
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication 
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency     
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group               
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa mRNA Influenza Vaccines Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product Type              
      1. Standalone mRNA Influenza Vaccines Market
      2. Combination mRNA Influenza Vaccines Market
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication    
      1. Seasonal Influenza
      2. Pre-pandemic/Pandemic Influenza
      3. Broad-Spectrum/Universal Influenza
      4. Others
    3. Market Analysis, Insights and Forecast – By Technology
      1. Conventional Non-replicating mRNA
      2. Self-Amplifying mRNA
      3. Trans-Amplifying/Replicon RNA
      4. Others
    4. Market Analysis, Insights and Forecast – By Valency         
      1. Monovalent
      2. Trivalent
      3. Quadrivalent
      4. Others
    5. Market Analysis, Insights and Forecast – By Age Group   
      1. Pediatric (<18 Years)
      2. 18–49 Years
      3. 50–64 Years
      4. ≥65 Years
    6. Market Analysis, Insights and Forecast – By Distribution Channel              
      1. Government & Public Health Programs
      2. Hospitals & Vaccination Clinics
      3. Retail Pharmacies & Drug Stores
      4. Others
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of the Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Moderna, Inc.
      2. GSK plc
      3. Pfizer Inc.
      4. Arcturus Therapeutics Holdings Inc.
      5. BioNTech SE
      6. SANOFI
      7. AstraZeneca PLC
      8. CanSino Biologics Inc.
      9. Ethris GmbH
      10. CSL
      11. Tiba Biotech LLC
      12. AIM Vaccine Co., Ltd.
      13. Immorna (Hangzhou) Biotechnology Co., Ltd.
      14. RNACure BioPharma (Shanghai) Co., Ltd. 
      15. Merck & Co., Inc.
Read Less

Figure 1:  Global mRNA Influenza Vaccines Market Revenue Breakdown (USD Million, %) By Region, 2025 & 2034

Figure 2:  Global mRNA Influenza Vaccines Market Value Share (%), By Product Type, 2025 & 2034

Figure 3:  Global mRNA Influenza Vaccines Market Value Share (%), By Indication, 2025 & 2034

Figure 4:  Global mRNA Influenza Vaccines Market Value Share (%), By Technology, 2025 & 2034

Figure 5:  Global mRNA Influenza Vaccines Market Value Share (%), By Valency, 2025 & 2034

Figure 6:  Global mRNA Influenza Vaccines Market Value Share (%), By Age Group, 2025 & 2034

Figure 7:  Global mRNA Influenza Vaccines Market Value Share (%), By Distribution Channel, 2025 & 2034

Figure 8:  Global mRNA Influenza Vaccines Market Value Share (%), By Region, 2025 & 2034

Figure 9:  North America mRNA Influenza Vaccines Market Value (USD Million), By Product Type, 2025 & 2034

Figure 10:  North America mRNA Influenza Vaccines Market Value Share (%), By Product Type, 2025

Figure 11:  North America mRNA Influenza Vaccines Market Value (USD Million), By Indication 2025 & 2034

Figure 12:  North America mRNA Influenza Vaccines Market Value Share (%), By Indication 2025

Figure 13:  North America mRNA Influenza Vaccines Market Value (USD Million), By Technology, 2025 & 2034

Figure 14:  North America mRNA Influenza Vaccines Market Value Share (%), By Technology, 2025

Figure 15:  North America mRNA Influenza Vaccines Market Value (USD Million), By Valency, 2025 & 2034

Figure 16:  North America mRNA Influenza Vaccines Market Value Share (%), By Valency, 2025

Figure 17:  North America mRNA Influenza Vaccines Market Value (USD Million), By Age Group, 2025 & 2034

Figure 18:  North America mRNA Influenza Vaccines Market Value Share (%), By Age Group, 2025

Figure 19:  North America mRNA Influenza Vaccines Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 20:  North America mRNA Influenza Vaccines Market Value Share (%), By Distribution Channel, 2025

Figure 21:  North America mRNA Influenza Vaccines Market Value (USD Million), By Country, 2025 & 2034

Figure 22:  North America mRNA Influenza Vaccines Market Value Share (%), By Country, 2025

Figure 23:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Product Type, 2025 & 2034

Figure 24:  Europe mRNA Influenza Vaccines Market Value Share (%), By Product Type, 2025

Figure 25:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Indication 2025 & 2034

Figure 26:  Europe mRNA Influenza Vaccines Market Value Share (%), By Indication 2025

Figure 27:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Technology, 2025 & 2034

Figure 28:  Europe mRNA Influenza Vaccines Market Value Share (%), By Technology, 2025

Figure 29:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Valency, 2025 & 2034

Figure 30:  Europe mRNA Influenza Vaccines Market Value Share (%), By Valency, 2025

Figure 31:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Age Group, 2025 & 2034

Figure 32:  Europe mRNA Influenza Vaccines Market Value Share (%), By Age Group, 2025

Figure 33:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 34:  Europe mRNA Influenza Vaccines Market Value Share (%), By Distribution Channel, 2025

Figure 35:  Europe mRNA Influenza Vaccines Market Value (USD Million), By Country/ Sub-region, 2025 & 2034

Figure 36:  Europe mRNA Influenza Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 37:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Product Type, 2025 & 2034

Figure 38:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Product Type, 2025

Figure 39:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Indication 2025 & 2034

Figure 40:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Indication 2025

Figure 41:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Technology, 2025 & 2034

Figure 42:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Technology, 2025

Figure 43:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Valency, 2025 & 2034

Figure 44:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Valency, 2025

Figure 45:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Age Group, 2025 & 2034

Figure 46:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Age Group, 2025

Figure 47:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 48:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Distribution Channel, 2025

Figure 49:  Asia Pacific mRNA Influenza Vaccines Market Value (USD Million), By Country/ Sub-region, 2025 & 2034

Figure 50:  Asia Pacific mRNA Influenza Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 51:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Product Type, 2025 & 2034

Figure 52:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Product Type, 2025

Figure 53:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Indication 2025 & 2034

Figure 54:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Indication 2025

Figure 55:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Technology, 2025 & 2034

Figure 56:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Technology, 2025

Figure 57:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Valency, 2025 & 2034

Figure 58:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Valency, 2025

Figure 59:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Age Group, 2025 & 2034

Figure 60:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Age Group, 2025

Figure 61:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 62:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Distribution Channel, 2025

Figure 63:  Latin America mRNA Influenza Vaccines Market Value (USD Million), By Country/ Sub-region, 2025 & 2034

Figure 64:  Latin America mRNA Influenza Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 65:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Product Type, 2025 & 2034

Figure 66:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Product Type, 2025

Figure 67:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Indication 2025 & 2034

Figure 68:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Indication 2025

Figure 69:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Technology, 2025 & 2034

Figure 70:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Technology, 2025

Figure 71:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Valency, 2025 & 2034

Figure 72:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Valency, 2025

Figure 73:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Age Group, 2025 & 2034

Figure 74:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Age Group, 2025

Figure 75:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 76:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Distribution Channel, 2025

Figure 77:  Middle East & Africa mRNA Influenza Vaccines Market Value (USD Million), By Country/ Sub-region, 2025 & 2034

Figure 78:  Middle East & Africa mRNA Influenza Vaccines Market Value Share (%), By Country/ Sub-region, 2025

Figure 79:  Global mRNA Influenza Vaccines Market Share (%), By Company, 2025

Table 1:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Product Type, 2021–2034

Table 2:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Indication 2021–2034

Table 3:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Technology, 2021–2034

Table 4:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Valency, 2021–2034

Table 5:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Age Group, 2021–2034

Table 6:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Distribution Channel, 2021–2034

Table 7:  Global mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Region, 2021-2034

Table 8:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Product Type, 2021–2034

Table 9:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Indication 2021–2034

Table 10:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Technology, 2021–2034

Table 11:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Valency, 2021–2034

Table 12:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Age Group, 2021–2034

Table 13:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Distribution Channel, 2021–2034

Table 14:  North America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Country, 2021-2034

Table 15:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Product Type, 2021–2034

Table 16:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Indication 2021–2034

Table 17:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Technology, 2021–2034

Table 18:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Valency, 2021–2034

Table 19:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Age Group, 2021–2034

Table 20:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Distribution Channel, 2021–2034

Table 21:  Europe mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034

Table 22:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Product Type, 2021–2034

Table 23:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Indication 2021–2034

Table 24:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Technology, 2021–2034

Table 25:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Valency, 2021–2034

Table 26:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Age Group, 2021–2034

Table 27:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Distribution Channel, 2021–2034

Table 28:  Asia Pacific mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034

Table 29:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Product Type, 2021–2034

Table 30:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Indication 2021–2034

Table 31:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Technology, 2021–2034

Table 32:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Valency, 2021–2034

Table 33:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Age Group, 2021–2034

Table 34:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Distribution Channel, 2021–2034

Table 35:  Latin America mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034

Table 36:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Product Type, 2021–2034

Table 37:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Indication 2021–2034

Table 38:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Technology, 2021–2034

Table 39:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Valency, 2021–2034

Table 40:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Age Group, 2021–2034

Table 41:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Distribution Channel, 2021–2034

Table 42:  Middle East & Africa mRNA Influenza Vaccines Market Revenue (USD Million) Forecast, By Country/ Sub-region, 2021-2034

mRNA Influenza Vaccines Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Mail icon

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Customize Now
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports